Tenoxicam PSUSA ends in 'maintenance': what a quiet outcome means for PV teams

What happened

On 30 October 2026 the European Medicines Agency published the outcome of a periodic safety update report single assessment (PSUSA) for tenoxicam. The listed regulatory outcome is "maintenance", meaning the marketing authorisations concerned are to stay in place.

The record we have is brief. It confirms the outcome and nothing more. It does not say whether the assessment led to any change in product information, whether new risk-minimisation measures were considered, or what safety data the reviewers examined. Those details sit in the full PSUSA documentation on the EMA site, and MAHs should read that before drawing conclusions about their own products.

Reading a 'maintenance' result

A PSUSA allows EU regulators to assess periodic safety update reports for the same active substance in one procedure. This applies even when products are authorised through different national routes. The procedure ends in an outcome for the authorisations concerned. 'Maintenance' is the most routine of these: the benefit-risk balance is not judged to require a change to the authorisation status.

'Maintenance' should not be read as 'nothing to do'. In general terms, a PSUSA outcome can sit alongside variations to the product information, and MAHs usually have follow-up obligations once the outcome is published. The tenoxicam record does not say whether any such steps apply here. Until MAHs have checked the full outcome documents, they should treat that question as open rather than assume the answer is no.

The same day, the same outcome, several substances

Tenoxicam was not alone. EMA published PSUSA outcomes with a 'maintenance' result for gliclazide, for nitrofurantoin and nitrofurantoin/pyridoxine hydrochloride, and for cystine/pyridoxine hydrochloride. The gliclazide and nitrofurantoin records also mention a list of nationally authorised products. The tenoxicam record does not.

Taken together, the batch shows how much of the PSUSA system consists of confirmations. Most periodic review outcomes keep the existing authorisations in place. For PV departments this is the everyday workload: reports are assessed, outcomes are posted, and the job is to check them against internal records rather than to respond to a crisis.

Where regulators are looking instead

The same week, PRAC opened two new safety reviews at its October 2026 meeting, according to EMA and AIFA. One is a referral on flupentixol/melitracen (Deanxit), prompted by serious neurological and psychiatric effects as described by AIFA. The other is a review of hypersensitivity reports linked to batches of human normal immunoglobulin medicines. EMA describes it as covering hypersensitivity clusters across all products in that class. Outcomes of both reviews are not yet known.

The contrast is useful. Routine PSUSAs close without drama, while the active signals are handled through referral or review procedures. For a QPPV, the tenoxicam outcome needs a documented check, not an escalation. The Deanxit and immunoglobulin reviews may need more: monitoring of case flow, readiness for information requests and awareness of what the committee may ask of MAHs. We cannot say yet what those requests will be.

EMA also issued a list of centrally authorised products with safety-related product information changes, dated 30 October 2026. The record does not name the products, so PV teams with centrally authorised products should check the list directly.

Reporting culture and data quality

Two other items bear on the quality of safety data. The Paul-Ehrlich-Institut and BfArM have backed the international #MedSafetyWeek campaign, running 2–8 November, which urges professionals and patients to report suspected side effects so that risks are spotted earlier. MAHs that take part in or amplify such campaigns should be ready for a possible rise in spontaneous reports. The records do not say whether a rise is expected, so this is a planning consideration rather than a forecast.

Separately, FDA has flagged a most-serious-category recall of four lots of Werfen's HemosIL AcuStar HIT-IgG(PF4-H) assay for heparin-induced thrombocytopenia. FDA says the lots show a negative bias that routine calibration and quality control may miss, and a supply interruption is expected. This is a device matter and not part of the tenoxicam procedure. Still, it is a reminder that case assessment can depend on laboratory results, and that a diagnostic problem can affect how well a suspected adverse reaction is confirmed. Teams handling such cases may want to check whether any affected lots appear in their source data.